Compare ROAD & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ROAD | BLCO |
|---|---|---|
| Founded | 2001 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Ophthalmic Goods |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 6.0B |
| IPO Year | 2018 | 2022 |
| Metric | ROAD | BLCO |
|---|---|---|
| Price | $121.17 | $17.51 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 12 |
| Target Price | ★ $124.20 | $18.55 |
| AVG Volume (30 Days) | ★ 531.8K | 438.6K |
| Earning Date | 04-30-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 40.46 | N/A |
| EPS | ★ 0.31 | N/A |
| Revenue | $785,679,000.00 | ★ $5,101,000,000.00 |
| Revenue This Year | $27.62 | $8.61 |
| Revenue Next Year | $9.86 | $5.52 |
| P/E Ratio | $394.76 | ★ N/A |
| Revenue Growth | 0.31 | ★ 6.47 |
| 52 Week Low | $64.79 | $10.45 |
| 52 Week High | $141.90 | $18.92 |
| Indicator | ROAD | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 43.02 | 48.74 |
| Support Level | $114.33 | $16.35 |
| Resistance Level | $123.52 | $17.66 |
| Average True Range (ATR) | 5.97 | 0.49 |
| MACD | -2.33 | -0.12 |
| Stochastic Oscillator | 20.07 | 31.12 |
Construction Partners Inc operates as a civil infrastructure company. It specializes in the construction and maintenance of roadways. The company through its subsidiaries, provides various products and services to both public and private infrastructure projects, with an emphasis on highways, roads, bridges, airports, and commercial and residential developments. Its operations consist of manufacturing and distributing hot mix asphalt, paving activities, including the construction of roadway base layers and application of asphalt pavement, site development, including the installation of utility and drainage systems, and others. The company has a single segment which predominantly consists of infrastructure and road construction, and operates across various states in the United States.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.